it will be better for sure :) additional 700 rooms from the new The Waterfront hotel will be added when its completed and Hard Rock Hotel is not the only hotel to be refurbished as there are a few more undergoing refurbishments.

we have been waiting for Genting's financial performance to be released and no harm waiting for a few more days, Jk. We just need to be aware of short term earnings disruptions from GenS and recovery from GenS is expected early of next year. As for index constituents changes, Gamuda is set to replace GenM and there should be volatility resulting from index funds rebalancing. There should be changes to reserve list too.

GenP / Plantation segment results is out and did not disappoint. This segment should continue to report similar strength at least until Q2'25. GenS recovery will take over thereafter and if the supply/demand for cpo remains tight by Q2'25, the plantation segment will continue to report similar strength in its results. else, normalization is expected. GenM is up next followed by RWLVS which is part of Genting's results. RWLVS should be flattish in Q3 and better in Q4 driven by F1 event; seasonally driven.

FY24 for GenP will be better than FY23. FY25 pretty much depends on the supply/demand situation towards mid of 2025. You may want to keep an eye on it. Looking good so far judging by FCPO trend without looking at the production/export/inventories data from MPOB and Indonesian palm oil association (GAPKI).

Yes, it is jk :) It should be similar in Q4 for GenS flattish against q2 as the new attractions and refurbished all-suite luxury hotel will be opened early of next year, better for RWLVS against Q3 (due to F1), GenM Malaysia segment should be better than Q3 due to holiday season.

yes it is, jk. Should be mid to high 200 due to festive season and F1. Its ok to use 200M as your own expectation. and FY24 eps will be trending to 33 cents based on 200M net profit for Q4. 3rd consecutive year of improvement. full year net profit estimate of 1.3bil for FY24 and PE15 will give you a high price 5.02. I think Genting's recovery from the pandemic is picking up steam.

My situation could be different compared to yours as I have just joined at 4.02, Vin. Putting aside the difference in our entry price and the result is meeting our discussion previously which is within 200M to 300M range :) If you look at the net cash from operating activities: 5.3bil versus 5.0bil comparing the same 9 months in FY24 and FY23; that is real money that Genting can spend :) By Q4, i believed the net cash from operating activities will reach 7.3bil at min. I will be eyeing for opportunity to add on :)

You are welcome, Vin. Q1'25 will see improved earnings from Gens but I think Q2'25 will be able to give a sneak preview of how big is the growth of RWS2.0; all suite luxury hotel is not the only hotel refurbished/to be built :) we may see 8bil qtrly revenue by 2026?

Not yet. GenM is confirmed; based on 25th Nov closing price; triggered market cap rule and Gamuda is the replacement. As for Genting, it did not fall to 36th position at the close of 25th Nov. FTSE will announce it today. If FTSE decides to add 99smart, then, Genting will be removed.

wah... that's a tough question ooh, Nick. Did a bit of calculations and bought it. I was just thinking its cheap - steady stream of dividend income while waiting for growth. No idea whether its right or wrong but I have considered some extreme simulations; stress test if you will - KLCI market crash by 40% and earnings disruptions similar to Covid. Just need to monitor how it evolves over time and make the necessary decision if there are changes to the variables/reasons that led me to investing in it. All is well and so far so good; manageable if you will.

Yup... Today's performance is phenomenal looking at the candlestick pattern for the first half, Jk. The pessimistic faction against the optimistic faction :) The optimistic faction pushes high and pessimistic pushes it down again. May the force be with the winner which should be followed through by confirmation.

Oceanarium and the all suite luxury hotel replacing Hard Rock Hotel will be opened first half of 2025 too. GenS earnings disruptions starting Q2'24 will be recovered by then; followed by earnings growth as more attractions being launched including additional hotel rooms capacity.

You are welcome, Vin, Jk. Its good that there are more clarity to RWS2.0 development now including exact opening date. The same goes with the BOD line up for RWLV which pahang kia shared. The timing of the announcement seems to be pointing to part of the remediation plan for the complaints. As for the trends today, its not shooting star per se. Take it as inverted hammer. Its easier to interpret the market psychology - optimistic faction pushes high and pessimistic faction pushes down; the bull versus bear :) The winner in the following week will determine the direction moving forward.

Take the announcement as part of the actions put in place in the response to the complaints, pahang kia. Dedicated oversight team if you will. And LKT and his leadership team is really smart in announcing the RWLV BODs :) Thumbs-up!

I think RWLV complaints will have a positive closure soon, Vin. Have a look at their BODs. One of them caught my attention - A. G. Burnett :) currently a Partner in the Gaming & Administrative Law Group with McDonald Carano. Prior to joining McDonald Carano, Burnett served as the Chairman of the Nevada Gaming Control Board (NGCB) from 2012 through 2017, and as a Member of the NGCB from 2011 to 2012. He also served as a member of the Governor's Gaming Policy Committee.

As for HMTM, TauRx will have to wait for the result of their marketing authorization approval from UK MHRA. It will be out of the 150 days if there is no announcement from UK MHRA by end of Jan'25; may take a few more months. GenS recovery would have started by then.

these are drugs that gets into human body, Vin :) It has to be reviewed thoroughly before being approved. Different authority may have different practices. The US FDA allow public to dial in/join the call for any new drugs data review prior to approval :) none for UK MHRA and UK MHRA depends on Commission on Human Medicines for the review of such new drugs/meds if I am not mistaken.

you are welcome, Vin. the plunge started in Aug driven by Gen S near term earnings disruption, RWLV complaints and index funds rebalancing which will be completed before 23rd Dec. Should be marching towards RM4 when GenS showing signs of recovery - Q2'25 if not Q1'25; when new attractions being opened to the public.